ArticleEmerging infectious diseases2015
Role of Maternal Antibodies in Infants with Severe Diseases Related to Human Parechovirus Type 3.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Detection rate, clinical characteristics, and molecular characterization of enterovirus and parechovirus infections in Thai infants during the first three months of life.Virology journal · 2026Article
- Neonatal Sepsis Caused by Human Parechovirus Type A3 With Marked Hyperferritinemia: A Case Report.Case reports in pediatrics · 2025Article
- Prevalence and genetic diversity of Parechovirus.Virus research · 2024Article
- Neutralizing activity of intravenous immune globulin products against enterovirus D68 strains isolated in Japan.BMC infectious diseases · 2023Article
- Novel Human Parechovirus 3 Diversity, Recombination, and Clinical Impact Across 7 Years: An Australian Story.The Journal of infectious diseases · 2023Article
- Human Parechovirus Associated Critical Illness in Neonates and Infants: Case Series and Review of Literature.Kansas journal of medicine · 2023Article
- Performance of Nanopore and Illumina Metagenomic Sequencing for Pathogen Detection and Transcriptome Analysis in Infantile Central Nervous System Infections.Open forum infectious diseases · 2022Article
- Development of Novel PCR Assays for Improved Detection of Enterovirus D68.Journal of clinical microbiology · 2021Article
- Review
- Evolutionary analysis of human parechovirus type 3 and clinical outcomes of infection during the 2017-18 Australian epidemic.Scientific reports · 2019Article
- Seroepidemiology of Parechovirus A3 Neutralizing Antibodies, Australia, the Netherlands, and United States.Emerging infectious diseases · 2019Article
- Human Parechovirus 1, 3 and 4 Neutralizing Antibodies in Dutch Mothers and Infants and Their Role in Protection Against Disease.The Pediatric infectious disease journal · 2018Article
- Urinary β2-microglobulin as an early marker of infantile enterovirus and human parechovirus infections.Medicine · 2018Observational
- Severe Parechovirus 3 Infections in Young Infants-Kansas and Missouri, 2014.Journal of the Pediatric Infectious Diseases Society · 2018Article
- Human Parechovirus: an Increasingly Recognized Cause of Sepsis-Like Illness in Young Infants.Clinical microbiology reviews · 2018Review
- Polarized Entry of Human Parechoviruses in the Airway Epithelium.Frontiers in cellular and infection microbiology · 2018Article
- Strain-dependent neutralization reveals antigenic variation of human parechovirus 3.Scientific reports · 2017Article
- Evolutionary and network analysis of virus sequences from infants infected with an Australian recombinant strain of human parechovirus type 3.Scientific reports · 2017Article
- An outbreak of severe infections among Australian infants caused by a novel recombinant strain of human parechovirus type 3.Scientific reports · 2017Article
- Seropositivity and epidemiology of human parechovirus types 1, 3, and 6 in Japan.Epidemiology and infection · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human parechovirus type 3 (HPeV3) is an emerging pathogen that causes sepsis and meningoencephalitis in young infants. To test the hypothesis that maternal antibodies can protect this population, we measured neutralizing antibody titers (NATs) to HPeV3 and other genotypes (HPeV1 and HPeV6) in 175 cord blood samples in Japan. The seropositivity rate (≥1:32) for HPeV3 was 61%, similar to that for the other genotypes, but decreased significantly as maternal age increased (p<0.001). Furthermore, during the 2014 HPeV3 epidemic, prospective measurement of NATs to HPeV3 in 45 patients with severe diseases caused by HPeV3 infection showed low NATs (≤1:16) at onset and persistently high NATs (≥1:512) until age 6 months. All intravenous immunoglobulin samples tested elicited high NATs to HPeV3. Our findings indicate that maternal antibodies to HPeV3 may help protect young infants from severe diseases related to HPeV3 and that antibody supplementation may benefit these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.